ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year-end

immunitybio-shares-climb-as-bladder-cancer-trial-nears-full-enrollment,-bla-submission-expected-by-year-end
Team of product research and develop in white sterile uniforms of medicine industry or electronics parts or food and drink product or cosmetic manufacturing plants or packaging factory, discuss about product or production process in production line at fac

Chatchai Limjareon

ImmunityBio (IBRX) on Friday said that enrollment in its registrational QUILT-2.005 trial for BCG-naïve non-muscle-invasive bladder cancer has surpassed expectations, with more than 85% of patients enrolled and full enrollment expected by Q2 2026.

The company’s shares climbed 25% in premarket